Trial Profile

Safety Evaluation of Intravenous Talineuren (TLN) in Parkinson's Disease-affected Patients

Status: Active, no longer recruiting

Phase of Trial: Phase I

Latest Information Update: 19 Mar 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Liposomal GM1-InnoMedica (Primary)
Indications Parkinson's disease
Focus Adverse reactions
Acronyms NEON
Sponsors InnoMedica

Most Recent Events

13 Mar 2024 Primary safety end-points will be analyzed at 134 weeks instead of 86 weeks. The Optional treatment prolongations may be done for 12 months also as per Amendment 5.
13 Mar 2024 Planned End Date changed from 1 Aug 2024 to 1 Aug 2025.
13 Mar 2024 Planned primary completion date changed from 1 Aug 2024 to 1 Aug 2025.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com